The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
An article from
Dive Brief
The RNA-focused drugmaker says Inceptive’s tools will help prioritize the best development options as well as speed up the research process.
Published June 4, 2026
By
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Alnylam Pharmaceuticals (
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam signs its first AI discovery deal with RNA specialist Inceptive
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
AI titans push Congress for DNA safeguards
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Legend Biotech emerged as a rare market winner
Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Ingenix Raises €13m From Sofinnova Partners-Led Syndicate to Scale Modality Fusion, a Novel Architecture for Drug Development
Alnylam stock rises after a $2 billion AI-driven RNAi drug discovery collaboration with Inceptive as analysts maintain bullish…
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if…
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity…
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
Delaware-based Incyte is now turning to AI to power through the coming decades.
